HER2/ErbB2 Antibody 10 Publications

Rabbit Polyclonal| Catalog number: 18299-1-AP

  • Print page
  • Download PDF

Be the first to review this product


-_-

Freight/Packing

Con: 53 μg/150 μl

Choose size:

Please visit your regions distributor:


Species specificity:
human, mouse

Positive WB detected in:
HeLa cells, SGC-7901 cells

Positive IP detected in:
SGC-7901 cells

Positive IHC detected in:
human breast cancer tissue, human spleen tissue, human testis tissue, human kidney tissue, human lung tissue

Positive IF detected in:
human breast cancer tissue

Positive FC detected in:
MCF-7 cells

Recommended dilution:
WB : 1:1000-1:4000
IP : 0.5-4.0 ug for IP and 1:500-1:1000 for WB
IHC : 1:50-1:200
IF : 1:50-1:500

Product Information


Source:
Rabbit

Purification method:
Antigen affinity purification

Isotype:
IgG

Storage:
PBS with 0.02% sodium azide and 50% glycerol pH 7.3. Store at -20oC. Aliquoting is unnecessary for -20oC storage.

Immunogen Information


Immunogen:
Peptide

Full name:
v-erb-b2 erythroblastic leukemia viral oncogene homolog 2, neuro/glioblastoma derived oncogene homolog (avian)

Calculated molecular weight:
138 kDa

Observed molecular weight:
185 kDa

GenBank accession number:

Gene ID (NCBI):

Gene symbol
ERBB2

Synonyms
CD340, ERBB2, HER 2, HER 2/neu, HER2, MLN 19, MLN19, NEU, NGL, p185, p185erbB2, Proto oncogene c ErbB 2, Proto oncogene Neu, TKR1
Background

HER2, also known as ErbB2 and Neu, is a 185-kDa transmembrane glycoprotein that is a member of the epidermal growth factor (EGF) receptor family of receptor tyrosine kinases. It has no ligand binding domain of its own and therefore cannot bind growth factors. However, it does bind tightly to other ligand-bound EGF receptor family members to form a heterodimer, stabilizing ligand binding and enhancing kinase- mediated activation of downstream signalling pathways, such as those involving mitogen-activated protein kinase and phosphatidylinositol-3 kinase. Amplification and/or overexpression of HER2 have been reported in numerous cancers, including breast and ovarian tumors. HER2 is a therapeutic target for the treatment of breast cancer and other carcinomas. This antibody raised against a synthesized peptide corresponding to 1237-1255aa of human HER2 recognizes the 185-kDa full-length glycosylated form and other lower molecular-mass forms of HER2, including the truncated form.


Back
to top